References
- PanagouliasGSDoupisJClinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combinationPatient Prefer Adherence2014822723624627627
- UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet19983528548659742977
- SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Eng J Med201336913171326
- AstraZeneca and Bristol-Myers Squibb announce top line results for SAVOR-TIMI-53 cardiovascular outcomes trial of Onlyza®(saxagliptin) Available from: http://news.bms.com/press-release/astrazeneca-and-bristol-myers-squibb-announce-top-line-results-savor-timi-53-cardiovasAccessed February 18, 2014
- WuSHopperISkibaMKrumHDipeptidyl peptidase-inhibitors and cardiovascular outcomes: a meta-analysis of randomized clinical trials Available from: http://www.asceptasm.com/wp-content/uploads/2013/06/ASCEPT-abstracts-202-315.pdfAccessed February 27, 2014
References
- DoggrellSAClinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metforminPatient Prefer Adherence20148473475
- PanagouliasGSDoupisJClinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combinationPatient Prefer Adherence2014822723624627627
- SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Eng J Med201336913171326
- WuSHopperISkibaMKrumHDipeptidyl peptidase-inhibitors and cardiovascular outcomes: a meta-analysis of randomized clinical trials Available from: http://www.asceptasm.com/wp-content/uploads/2013/06/ASCEPT-abstracts-202-315.pdfAccessed February 27, 2014